entertainment -WSS

entertainment

author：entertainment 2025-09-27 13:11:11 - browse：59683

A dosage of Wegovy, a drug used for weight loss — Amanda Andrade-Rhoades/AP

U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment.

The new label indicates that Wegovy can be used to reduce the risk of major heart complications — including heart attack, stroke, or cardiovascular-related deaths — for people with overweight or obesity and existing heart disease, Novo said in a statement Friday.

The decision was based on results of a large, five-year trial that showed Wegovy cut the risk of cardiovascular problems by 20% in that population. This is the first time a weight loss treatment has been approved to also help improve heart outcomes, the FDA said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Medical student insurance fails on mental health care coverage

WSS

How AI helped researchers track recovery from depression

Experts study whether long Covid risk adds up with each reinfection

CMS should re

Experts study whether long Covid risk adds up with each reinfection

What Congress can do to address the rural doctor shortage

Why sickle cell disease is getting the first CRISPR treatment

leisure time

entertainment

focus

Moonlake's readout produced a cash windfall. Risks remain

After sickle

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Second xenotransplant done with gene

Malaria cases in Florida and Texas: Here’s what you need to know

STAT Virtual Event: Putting AI to the Test

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Ukraine and a new approach to mental health in war

United colonoscopy coverage change 'may cost lives,' doctors say

EpiPen alternative approval delay highlights citizen petition issue

entertainment

Spinal cord stimulation reduces pain in amputees, study finds

Leukemia patients are helped by Syndax's new type of therapy

How AI helped researchers track recovery from depression

Senate HELP committee spars over health care workforce policies

Changes to biosimilar regulatory framework must prioritize patients

Experts study whether long Covid risk adds up with each reinfection

explore

explore

hotspot

focus